MX2018011349A - Uso de masitinib para el tratamiento de una subpoblacion de pacientes con esclerosis lateral amiotrofica. - Google Patents

Uso de masitinib para el tratamiento de una subpoblacion de pacientes con esclerosis lateral amiotrofica.

Info

Publication number
MX2018011349A
MX2018011349A MX2018011349A MX2018011349A MX2018011349A MX 2018011349 A MX2018011349 A MX 2018011349A MX 2018011349 A MX2018011349 A MX 2018011349A MX 2018011349 A MX2018011349 A MX 2018011349A MX 2018011349 A MX2018011349 A MX 2018011349A
Authority
MX
Mexico
Prior art keywords
lateral sclerosis
amyotrophic lateral
masitinib
treatment
patient subpopulation
Prior art date
Application number
MX2018011349A
Other languages
English (en)
Inventor
Moussy Alain
Pierre Kinet Jean
mansfield Colin
Original Assignee
Ab Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab Science filed Critical Ab Science
Publication of MX2018011349A publication Critical patent/MX2018011349A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente invención se refiere a un método para tratar pacientes con esclerosis lateral amiotrófica (ALS) no agresiva o moderadamente agresiva, cuya tasa de cambio de la Escala de Evaluación Funcional de la Esclerosis Lateral Amiotrófica (ALSFRS-R) revisada, antes del inicio del tratamiento es de <1.1 puntos por mes, comprendiendo dicho método administrar un inhibidor de tirosina cinasa o un inhibidor de mastocitos, en particular masitinib, o una sal o solvato farmacéuticamente aceptable del mismo, opcionalmente en combinación con al menos un ingrediente farmacéuticamente activo.
MX2018011349A 2016-03-25 2017-03-24 Uso de masitinib para el tratamiento de una subpoblacion de pacientes con esclerosis lateral amiotrofica. MX2018011349A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16162490 2016-03-25
PCT/EP2017/057134 WO2017162884A1 (en) 2016-03-25 2017-03-24 Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation

Publications (1)

Publication Number Publication Date
MX2018011349A true MX2018011349A (es) 2019-02-07

Family

ID=55637258

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011349A MX2018011349A (es) 2016-03-25 2017-03-24 Uso de masitinib para el tratamiento de una subpoblacion de pacientes con esclerosis lateral amiotrofica.

Country Status (20)

Country Link
US (1) US10092564B2 (es)
EP (1) EP3240538B1 (es)
JP (2) JP7250312B2 (es)
KR (1) KR102293847B1 (es)
CN (1) CN108883108B (es)
AU (1) AU2017236177B2 (es)
BR (1) BR112018069515A2 (es)
CA (1) CA3018635C (es)
DK (1) DK3240538T3 (es)
EA (1) EA038531B1 (es)
ES (1) ES2899929T3 (es)
HU (1) HUE057398T2 (es)
IL (1) IL261856B (es)
MX (1) MX2018011349A (es)
NZ (1) NZ745778A (es)
PL (1) PL3240538T3 (es)
PT (1) PT3240538T (es)
SG (1) SG11201808106YA (es)
SI (1) SI3240538T1 (es)
WO (1) WO2017162884A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
EP3563849A3 (en) 2012-10-25 2020-02-12 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
EP3060205A4 (en) 2013-10-22 2017-06-28 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CA3033079A1 (en) 2016-08-31 2018-03-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
EP3800471A1 (en) 2016-11-25 2021-04-07 Genuv Inc. Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same
KR20190128703A (ko) * 2017-03-28 2019-11-18 노파르티스 아게 다발 경화증 치료를 위한 새로운 방법
CN111328283A (zh) * 2017-05-30 2020-06-23 德西费拉制药有限责任公司 1-[4-溴-5-[1-乙基-7-(甲氨基)-2-氧代-1，2-二氢-1，6-萘啶-3-基]-2-氟苯基]-3-苯基脲和类似物用于治疗与血小板衍生的生长因子受体α中的遗传异常相关的癌症的用途
JP7463281B2 (ja) * 2018-03-05 2024-04-08 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド コロニー刺激因子を標的とすることによる、緑内障および視神経症のための療法
CN113038944A (zh) 2018-07-02 2021-06-25 通用医疗公司 色甘酸钠和α-乳糖的粉末化制剂
CN112618717A (zh) * 2019-09-24 2021-04-09 北京大学深圳研究生院 Btk抑制剂用于治疗肌萎缩侧索硬化症的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (es) 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
ES2294344T3 (es) 2002-08-02 2008-04-01 Ab Science 2-(3-aminoaril)amino-4-aril-tiazoles y su utilizacion como inhibidores de c-kit.
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
WO2008098949A2 (en) 2007-02-13 2008-08-21 Ab Science Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors
AR080933A1 (es) 2010-04-20 2012-05-16 Ab Science Tratamiento de esclerosis multiple con masitinib
JP6145946B2 (ja) 2011-07-13 2017-06-14 サイトキネティックス， インコーポレイテッド 併用ａｌｓ療法
SI2903616T1 (en) * 2012-10-04 2018-02-28 Ab Science The use of masitinib in combination with gemcitabine for the treatment of a subgroup of patients suffering from foot-and-mouth disease
CA2902599C (en) * 2013-03-15 2023-03-21 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone compounds and methods of treating disorders
WO2015063318A1 (en) * 2013-11-04 2015-05-07 Ab Science Use of masitinib for treatment of amyotrophic lateral sclerosis

Also Published As

Publication number Publication date
AU2017236177B2 (en) 2022-03-31
CA3018635C (en) 2023-09-26
CN108883108A (zh) 2018-11-23
SG11201808106YA (en) 2018-10-30
BR112018069515A2 (pt) 2019-04-16
EP3240538B1 (en) 2021-09-29
PL3240538T3 (pl) 2022-01-31
IL261856B (en) 2022-04-01
EA201800499A1 (ru) 2019-03-29
AU2017236177A1 (en) 2018-09-20
EP3240538A1 (en) 2017-11-08
US10092564B2 (en) 2018-10-09
KR20180125966A (ko) 2018-11-26
EA038531B1 (ru) 2021-09-10
JP2022037132A (ja) 2022-03-08
PT3240538T (pt) 2021-12-07
SI3240538T1 (sl) 2022-02-28
US20180117037A1 (en) 2018-05-03
JP2019515884A (ja) 2019-06-13
CA3018635A1 (en) 2017-09-28
WO2017162884A1 (en) 2017-09-28
CN108883108B (zh) 2021-08-06
KR102293847B1 (ko) 2021-08-26
IL261856A (en) 2018-10-31
DK3240538T3 (da) 2021-12-06
NZ745778A (en) 2022-07-01
JP7250312B2 (ja) 2023-04-03
HUE057398T2 (hu) 2022-05-28
ES2899929T3 (es) 2022-03-15

Similar Documents

Publication Publication Date Title
MX2018011349A (es) Uso de masitinib para el tratamiento de una subpoblacion de pacientes con esclerosis lateral amiotrofica.
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX2021008342A (es) Derivados de pirazol como inhibidores de calicreina plasmatica.
PH12018500040A1 (en) Indazole and azaindazole compounds as irak-4 inhibitors
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
TR201901312T4 (tr) Mcl-1 proteinini inhibe eden tetrahidronaftalen türevleri.
TW201613919A (en) Inhibitors of Bruton&#39;s tyrosine kinase
NZ708593A (en) Novel pyrazole derivative
SG10201810401RA (en) Pharmaceutical combinations for treating cancer
IN2015DN00376A (es)
PH12020551597A1 (en) Treatment of hidradenitis suppurativa using jak inhibitors
MX2018005041A (es) Compuestos para tratar la esclerosis lateral amiotrofica.
MY181928A (en) Sodium channel modulators for the treatment of pain and diabetes
SG10201810404XA (en) Combination comprising a glucocorticoid and edo-s101
PH12016502353A1 (en) Pharmaceutical composition
MX2019008626A (es) Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-ilcarbamato como inhibidores de monoacilglicerol lipasa (magl).
JOP20190233A1 (ar) نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون
MY163235A (en) Pharmaceutical preparation containing pyridylaminoacetic acid compound
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
MA39765A (fr) Formulation pharmaceutique d&#39;un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d&#39;utilisation
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
GEP20227442B (en) Boron containing pde4 inhibitors
PH12019502660A1 (en) RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE
PH12019502510A1 (en) Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof
PH12018501285A1 (en) Alkyl dihydroquinoline sulfonamide compounds